Introduction {#s1}
============

The recent and rapid increase in the prevalence of chronic disease is a global concern, but a particular threat to health systems in developing countries. Rising prevalence of chronic diseases could destabilize not only health systems but entire state economies, which has been acknowledged at the highest levels.^[@SHORTS-12-029C1],[@SHORTS-12-029C2]^

Chronic obstructive pulmonary disease (COPD) is one of several diseases contributing to the rise of chronic illnesses. Typically it results from accumulated environmental exposure to particular irritants -- the best established links being with smoking, and domestic and outdoor pollution. More recently, interactions between tuberculosis, HIV and smoking have become of increasingly greater concern, as aetiological factors, as cases of HIV, tuberculosis and co-infection have risen.^[@SHORTS-12-029C3]^

That COPD is largely environmentally-driven, and thus potentially preventable, is particularly important in the face of unfavourable epidemiological reports. COPD accounted for 5% of deaths globally in 2005, with most of these occurring in low- and middle-income countries,^[@SHORTS-12-029C4]^ and it is predicted to become the third leading cause of death by 2030.^[@SHORTS-12-029C5]^ The outlook may become even worse if COPD associated with HIV/tuberculosis-related lung disease proves to be relatively resistant to existing treatments, and if issues associated with poor nutrition (which appears to be associated with poorer outcomes) cannot be resolved.^[@SHORTS-12-029C6]^ As a chronic disease, COPD also accrues vast numbers of disability-adjusted life years (DALYs). Most of these arise in the World Bank\'s 'South Asia' and 'East Asia' regions.^[@SHORTS-12-029C7]^

India suffers among the highest number of DALYs due to COPD.^[@SHORTS-12-029C8]^ The prevalence of COPD in India is not well understood, but we recently suggested the best existing estimates for chronic bronchitis (a commonly used proxy) indicate that prevalence is between 6.5% and 7.7% in the adult population -- although it is unlikely that this estimate would apply to all Indian subpopulations.^[@SHORTS-12-029C9]^ World Health Organization (WHO)-Government of India COPD management guidelines were produced in 2003,^[@SHORTS-12-029C7]^ but the extent of their implementation, and effect, are unknown. Outcomes have not obviously been reviewed or audited, and the guidance was largely drawn from similar international documents -- based on outcomes from trialled interventions in populations from other, generally more developed countries.

Review aims {#s1a}
-----------

We aimed to review the current quality of management of COPD in India by addressing the following questions: How is COPD in India currently managed?How effective is the current management of COPD in India?

Methods {#s2}
=======

The Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects (Cochrane Library), Database of Promoting Health Effectiveness Reviews (Evidence for Policy and Practice Information Centre) and Medline (via PubMed) were searched before conducting the review, on 30 October 2010, to ensure that there were no recent or ongoing reviews in the subject area. The review was then conducted according to the relevant aspects of the PRISMA guidance^[@SHORTS-12-029C10]^ and the guidance of the Centre for Reviews and Dissemination, York.^[@SHORTS-12-029C11]^

Following scoping searches a review protocol was developed describing the search strategy and methods for data collection and analysis. The review questions above were deconstructed to identify PICOS elements used to generate search terms (see Table [1](#SHORTS-12-029TB1){ref-type="table"}). The search strategy was trialled before use to determine that existing related well-cited articles would be returned, and adaptations made where necessary. Table 1PICOS identifiers from research questions ('key terms') and database -- and thesaurus-derived alternatives ('additional terms') used to generate database searchesPICOSKey termsAll populations resident in IndiaN/aN/aCOPDN/aAdditional terms generatedIndiaN/aN/aCOPD, COAD, chronic obstructive pulmonary disease, chronic obstructive airway disease, chronic obstructive airways disease, chronic obstructive lung disease, chronic bronchitis, 'bronchitis, chronic', emphysema\*, chronic airflow obstruction\*, 'airflow obstruction\*, chronic'N/a[^1]

Search {#s2a}
------

The PICOS identifiers and related terms (Table [1](#SHORTS-12-029TB1){ref-type="table"}) were used to search the Medline (via PubMed) and Embase (via Ovid) databases on 1 August 2011 (updated 22 December 2011), the IndMED database on 15 July 2012, Cochrane Central Register of Controlled Trials on 16 July 2012, and the CINAHL database on 24 July 2012. No restrictions were placed on language of publication, study design, publication type or publication status. Only studies published since 1980 were included, as our interest was in the recent situation, and earlier publications were also relatively few and difficult to access.

In addition, the available online contents (from 1980 onwards) of the journals *Lung India* and *Indian Journal of Chest Diseases and Allied Sciences* were hand-searched on 19 August 2011. Reference lists of included papers were scanned, as well as the references of relevant review articles/editorials identified in the search. Finally, we contacted experts in the field with the aim of identifying any additional or unpublished data. We did not include unpublished results available on trial databases as we felt unable to assess the data in a sufficiently useful manner, due to lack of information such as location and dates of study, methodology, length of follow-up and general analytical approach. Many of the trials recruited from multiple countries and data for India alone were not available. We also felt unable to interpret data regarding adverse events sufficiently well.

Selection {#s2b}
---------

Inclusion/exclusion criteria for the results of the search are listed in Table [2](#SHORTS-12-029TB2){ref-type="table"}. Table 2Inclusion/exclusion criteriaIncludedExcludedAll categories (mild--very severe) of COPDManagement strategies relevant to management of chronic diseases generally, but not COPD specificallyManagement of chronic, stable COPDAll outcomes -- including those objectively and subjectively defined, and process and clinical measuresManagement strategies applicable to management of acute exacerbations of COPDReview articles without novel synthesis[^2]

Two subsets of results pertaining to Question 1 were acquired -- studies of primary and secondary prevention. The number of primary prevention studies returned was limited and we included them even though the interventions were not conceived to target COPD alone. In the series of secondary prevention studies returned, we made no exclusions based on intervention type, so long as the study pertained to the management of chronic, stable COPD, rather than acute events. Indeed, observation of the types of intervention pursued was of interest in itself. Similarly, regarding Question 2, we included studies of all measured outcomes, other than those relating to acute exacerbations alone.

To determine study eligibility, the titles and abstracts of all papers returned from the search were screened by one reviewer. The studies accepted at this point were reviewed fully, and progressed either to data extraction or exclusion. Those excluded were: reviews/editorials without additional analysis, studies wherein data were not COPD-specific, where populations were not representative of the general population, interventions were of acute management and/or studies were without actual trialled intervention, were not relevant, or not available (see Figure [1](#SHORTS-12-029F1){ref-type="fig"}). Figure 1Flow chart demonstrating handling of papers returned by Searches 1 and 2

Data extraction {#s2c}
---------------

Data extraction was performed using two proformas -- one for extraction of basic study data, one for quality assessment. The basic study data proforma was a modified version of the checklist recommended by the Centre for Reviews and Dissemination, York.^[@SHORTS-12-029C11]^ Our quality checklist has been used previously^[@SHORTS-12-029C9]^ and includes the 'component ratings' of the Effective Public Health Practice Project Quality Assessment Tool^[@SHORTS-12-029C12]^ and the bias assessment as recommended in the Cochrane Handbook.^[@SHORTS-12-029C13]^ It was used for all study types, with items omitted where not relevant. The proformas were tested on a subset of the papers, and iterations made, before being used for final data collection. The broad headings under which information was recorded for each study are listed in [Box 1](#BOX1){ref-type="boxed-text"}.

###### Data extraction and quality assessment checklists

The numbers beside the quality assessment criteria are used to indicate how quality for each criterion has been rated, in Tables 3--5. General data extractionQuality assessment checklistStudy dates (or publication date if not available)Study designType of reportNumber of participants (enrolled, excluded and lost to follow-up)Participant characteristics (including age, sex, smoking status, exposure to domestic fuels and socioeconomic status, where available)Study setting (location and urban or rural)Definition of diagnosis usedMeasurement/assessment toolOutcomes (including subgroup data for age, sex, urban/rural residence, smoking status and domestic fuel exposure where available)1. Type of report2. Clear aims/objectives3. Clear and appropriate methods, including sampling/recruitment (4), inclusion/exclusion criteria (5) and data collection6. Appropriate and rigorous analysis7. Outcomes not reported or additional outcomes reported8. Risk of bias in selection9. Risk of bias in measurement and outcomes10. Limitations discussed11. Funding information and information regarding conflicts of interest

One reviewer carried out the data extraction for basic study data. The results were checked by a second reviewer and any concerns remedied by re-checking to reach a consensus decision. Two reviewers independently performed the extraction of quality data, before the results were collated. Inconsistencies were resolved as above.

Quality assessment {#s2d}
------------------

The extracted quality data were used to grade each aspect of the assessment as 'good', 'poor' or 'non-assessable'. Again this rating was independently carried out by two reviewers. Disagreements were resolved by discussion and consensus decision. Where the combination of the number of 'poor/non-assessable' ratings and main reasons for concern were deemed sufficient to question the reliability of the study, the study was excluded from a secondary analysis (see below).

Data synthesis {#s2e}
--------------

As anticipated on preliminary searching, study designs were too heterogeneous to allow useful meta-analysis. Thus, a narrative approach was used. The data were summarized in tables, and analysed twice (before and after exclusion of studies where quality was of concern).

We aimed to assess each set of studies with regard to: Number of studies and time-trends in production and quality.We wanted to examine the management intervention studies to determine: Types of intervention trialled and levels of success;Any peculiarities of intervention effect by subgroup (age, sex, urban/rural location, smoking status and exposure to domestic fuels).And we aimed to examine the management outcome studies to determine: Outcome measures used;Extent and efficacy of current management strategies;Any differences in outcomes by subgroup.Proposals were formed based on general initial analysis outcomes, and inconsistencies examined. Finally, comparisons between results of the analyses were made before and after studies with quality concerns were excluded. Where data were insufficient to allow narrative synthesis, display and discussion of the data was used.

Results {#s3}
=======

The search produced 1096 papers for review. Figure [1](#SHORTS-12-029F1){ref-type="fig"} displays the handling of the search results.

The data extracted from each of the studies are summarized by question theme in Table [3](#SHORTS-12-029TB3){ref-type="table"} (primary prevention management interventions), Table [4](#SHORTS-12-029TB4){ref-type="table"} (secondary prevention management interventions) and Table [5](#SHORTS-12-029TB5){ref-type="table"} (management outcomes). The data excluded from the second analyses (due to quality concerns -- see Methods), are italicized, and the main quality concerns noted. Table 3Studies relating to primary prevention strategies for chronic obstructive pulmonary disease in IndiaRef.Study dates, design and locationPopulation size and characteristicsIntervention and methodsUnits of assessment, definitions and follow-upOutcomesQuality142010--2020; modelling studyn/a -- model based on all IndiaIntervention: 10 year programme to introduce 150 million low-emissions household cookstoves in India\
Methods: similar to WHO\'s Comparative Risk Assessment exercise -- applied to assess effect on healthUnits of assessment: deaths and DALYs avoidedDeaths from COPD avoided in 2020: 28.2%\
Number of deaths avoided 2010--2020: 1.27 × 10^6^\
DALYs avoided 2010--2020: 9%G: 1, 2, 3, 6, 7, 10, 11\
P:\
N:\
(NB 4, 5, 8 and 9 not listed due to nature of study)*15'from May 2007' (P2009); quasi-experimental study'; '11 villages, rural India'n* = *493; 14--24 years; 32% COPD and respiratory disorders, 12% tuberculosisIntervention:* *Tobacco de-addiction guidance/counselling offered by NGO*\
*Methods:* *Counselling effect monitored for four months (20 follow-up sessions conducted during course of study)Unit of assessment: discontinuation of tobacco use; reasons for starting tobacco use431 'showed positive attitude towards quitting tobacco use'; 410 discontinued tobacco use; 21 abstained for short-period, but re-started*\
*Of 431 with positive response: 84% started using tobacco due to peer pressure, 11% to imitate tobacco advertising on media/films/TVG:*\
*P: 1, 2, 3, 7, 10*\
*N: 4, 5, 6, 8, 9, 11*\
*Main concerns: abstract therefore limited information; objectives and methods particularly unclear*[^3][^4] Table 4Studies relating to secondary prevention strategies for chronic obstructive pulmonary disease in IndiaRef.Study dates, design and locationPopulation size and characteristicsIntervention and methodsAssessment/follow-up measuresMain outcomesQuality16P2010; RCT; Jaipur*n* = 33 (15 experimental, 18 control); mean age: 60.7 (SD 8.5) in sildenafil arm; 63.6 (SD 6.7) in placebo arm; patients with severe/very severe COPD by GOLD classification, \> 20 pack year history and pulmonary artery systolic P \> 40 mmHgIntervention: oral sildenafil TDS\
Methods: double blind, randomized, placebo-controlled; 12-week follow-up6MWD; pulmonary arterial pressureSildenafil group: 6MWD significantly higher at one and three months; pulmonary arterial pressure significantly lower at three months\
Placebo group: no change in either measureG: 1, 2, 3, 5, 6, 9\
P: 7, 10\
N: 4, 8, 11\
Main concerns: drug and placebo supplied by drug company, but extent of further input not mentioned*17P2011; quasi-experimental study; Dehradunn* = *20 (10 experimental, 10 control); 100 % men; 'severe' COPDIntervention: domiciliary pulmonary rehabilitation programme*\
*Methods: follow-up six monthsCCQ; 6MWD; spirometrySignificant differences between groups in CCQ scores and 6MWD from fourth month onwards (higher in intervention group); no significant difference in spirometryG: 1, 2, 5, 6, 7, 10*\
*P: 3, 4, 8,*\
*N: 9, 11*\
*Main concerns: non-randomized -- only willing participants in intervention group*182009--2010; parallel group study; Jamnagar*n* = 61; moderate-severe COPD\
Experimental group: mean age + SD: 58.39 + 8.58 years\
Control group: mean age + SD: 56.53 + 11.29 yearsIntervention: doxycycline daily\
Methods: randomized, single-blind; four weeks follow-upSpirometry, CRP, MRC dyspnoea scaleIntervention group: significant increase in FEV1 and FVC during study period; significantly greater improvement in spirometric parameters and reduction in baseline CRP cf. control group, no change in dyspnoea score\
Control group: No change in lung function parameters or dyspnoea scoreG: 1, 2, 4, 6, 7, 10\
P:\
N: 3, 5, 8, 9, 1119P2010; RCT; Mangalore*n* = 30 (10 in each group); 100% men; 45--75 years; clinically stableIntervention: upper-limb training, lower-limb training or upper and lower-limb training\
Methods: no controls; four-week follow-upUnsupported upper-limb endurance test; 6MWD\
CRQCompare to pretraining:\
Upper limb training: improved endurance test and CRQ;\
Lower limb training: improved 6MWD and CRQ; combined training: improved all outcomesG: 1, 5, 6, 7, 11\
P: 2, 3, 4, 10\
N: 8, 9\
Main concern: lack of information regarding training programme/intervention*20P2010; RCT; Chidambaramn* = *16 (7 experimental, 9 controls); 40--68 yearsIntervention: unsupported arm exercises 3x per week*\
*Methods: randomized; 1 month follow-up12MWD, spirometrySignificant improvement in FVC values in both groups, no change in FEV1 in either group*\
*'Significant' change in 12MWD -- NB direction of change unclear, one 'significant' value 'P* \< *0.053'G: 1, 2*\
*P: 6, 7, 9, 10*\
*N: 3, 4, 5, 8, 11*\
*Main concerns: small n-number, little information re methods, data not reported in results (only results of tests) therefore size/relevance of differences unclear, significance level unclear, conclusions not in line with results*21P2007; RCT; Mumbai/Pune*n* = 19; 89.5% men; mean age 59.15 (SD 7.98) years; stable moderate-severe COPD by GOLD criteriaIntervention: pMDI\
Methods: randomized, double-blind, placebo-controlled, cross-over study; single doses of tiotropium via pMDI plus spacer, and by DPI, and placebo administered on three separate days at least four days apart; 24 hour follow-upSpirometry, body plethysmographyFEV1, FVC and IC significantly higher in MDI and DPI cf placebo groups\
No differences between outcomes in MDI and PDI groupsG: 1, 2, 3, 5, 6, 7, 9, 11\
P: 10\
N: 4, 8*222006--2007; RCT; Chandigarhn* = *74 (42 experimental; 32 control); patients with mild COPD excluded*\
*Experimental group: 95.2% men; 36--80 (mean 60) years; 95.2% smokers*\
*Control group: 90.6% men; 35--83 (mean 61) years; 90.6% smokersIntervention: WHO-Government of India COPD guidelines*\
*Methods: controls received 'conventional' treatment; six months follow-upSGRQ: change of \> 4 units considered significantFollow-up scores significantly higher than baseline in both groups, and significantly higher postintervention cf. post control treatmentG: 1, 2, 4, 5, 10, 11*\
*P: 3, 6, 7, 9*\
*N: 8*\
*Main concern: some elements of methodology -- including recruitment and analysis -- not well described; not all outcomes reported; potential differences in disease phenotype between groups; control arm treatment not well described and administered by different individuals; high potential for bias*23P2006; RCT; Delhi*n* = 44; 100% men; 38--78 years; stable patients; eight mild, 19 moderate and 17 severe (by GOLD guidelines)Intervention: single doses of formoterol, ipratropium bromide or placebo\
Methods: randomized, double blind, crossover, placebo-controlled; treatments administered on three consecutive days in random order, follow-up one hourSpirometry, static lung volumes, heart rate, blood pressure and perceived dyspnoea assessmentFormoterol and ipratropium led to similar significant increases in FEV1 and FVC scores, improved static lung volumes and dyspnoea scoresPlacebo did not lead to significant improvements in any outcomeG: 1, 2, 3, 5, 6, 7, 9, 10\
P:\
N: 4, 8, 1124P2006; RCT; Chennai*n* = 105 (32 drug arm, 39 plant arm, 34 placebo arm); 100% men; 35--85 years; 'moderate' and stable diseaseIntervention: DCBT1234-Lung KR (plant extract), drug combination (salbutamol, theophylline and bromhexine) or placebo\
Methods: randomized, placebo controlled study; six-month follow-upSpirometry, ABG analysis, COPD symptomsDCBT1234-Lung KR led to significant improvement in FEV1 and Pa02; other treatments did not\
DCBT1234-Lung KR patients showed significant improvement in all clinical symptoms studies; drug treatment did not improve dyspnoea or disabilityG: 1, 2, 3, 5, 6, 7, 9\
P: 10, 11\
N: 4, 8\
Main concern: involvement of 'Dalmia Brothers Private Limited' not delineated*25P2006; RCT; Delhin* = *60 (31 experimental; 29 controls); 100% men; ex-smokers*\
*Experimental group: mean age: 26.94 (SD 8.79) years; duration of disease: 5.00 (SD 5.06) years*\
*Control group: mean age: 62.72 (SD 9.51) years; duration of disease: 9.52 (SD 4.36) yearsIntervention: oral prednisolone*\
*Methods: randomized study; seven days treatment, assessment on day 8Spirometry, bronchodilator responsivenessNo response to intervention found; no differences between groups foundG: 1, 2, 3, 6, 7, 10*\
*P: 8, 9*\
*N: 4, 5, 11*\
*Main concerns: significantly different mean age and duration of disease between intervention and control groups; not blinded, no placebo*26P2006; RCT; Kanpur*n* = 48 (24 per group)Intervention group: mean age 53.3 (SD 2.9) years; 78% men\
Control group: 51.1 years; 91% menIntervention: Pranayama yoga techniques\
Methods: randomized, single-blind; follow-up three monthsSpirometry, ABG, 6MWD, SGRQIntervention group: longer 6MWD, higher PEFR and lower SGRQ scores after training; no significant effect in other parameters\
Control group: no significant changes over study periodG: 1, 2, 4, 5, 6, 7, 9\
P: 10\
N: 3, 8, 11*27P2006; parallel group study; Delhin* = *32 (16 per group); severe COPD*\
*Tiotropium group: mean age 58.8 (SD 9.33) years*\
*Ipratropium group: 59.3 (SD 9.26) yearsIntervention: Daily tiotropium bromide or ipratropium bromide*\
*Methods: non-randomized, parallel group study (sequential design viz controls); six-week follow-up (plus 6 weeks preintervention)Spirometry, 6MWD, perceived dyspnoea, CRQNo obvious effect of either treatment (although analysis unclear -- see column 7)G:1, 2, 4*\
*P: 5, 6, 9, 10*\
*N: 3, 7, 8, 11*\
*Main concerns: recruitment not detailed, non-randomized, multiple comparisons, comparisons (and therefore outcomes) unclear; (potential) control period not analysed as such282005--2006; design unclear; Delhin* = *40 (20 experimental, 20 control); no information re participants reportedIntervention: 'Sharbat-e-Unsul Murakkab', dose unclear*\
*Methods: single blind, placebo-controlled; follow-up 21 days'History', PEFR, haemogram, eosinophil count, liver function tests, renal tests, sputum culture'Improvement' in cough, sleep disturbance, 'hypnotic effect', sputum purulence sputum volume, sputum viscosity, dyspnoea, rhonchi and PEFR in experimental, but not control, subjectsG: 1*\
*P:2, 6, 7, 9, 10*\
*N: 3,4, 5, 8, 11*\
*Main comments: study design (randomization) unclear, no information re participants, dose of drug not reported, outcome measures not defined, data collection methods unclear, non-significant results reported as significant, conclusions not in line with results*292004--2006; quasi-experimental study; Delhi*n* = 87; 100% men; mean age 64.8 years (SD 8.5); 28.7 % smokers, 54 % ex-smokers; never before received influenza vaccinationIntervention: influenza vaccination\
Methods: patients treated according to GOLD guidelines and followed up for one year pre- and postvaccinationExacerbations (diagnosis =increasing shortness of breath and increase in amount or purulence of sputum)Exacerbations due to 'natural infections' significantly lower post-vaccination (effectiveness = 60 %, 60 % and 75 %, in mild, moderate and severe COPD, respectively); outpatient and hospital admission lower postvaccinationG: 1, 2, 3, 5, 6, 7\
P: 8, 9, 10\
N: 4, 11\
Main concern: sequential study design30P2005; pilot study, unclear if randomized; Delhi*n* = 20; current smokers not willing to give up smoking excluded; stable patients with moderate to severe COPD attending outpatient department of tertiary care centre; little other information reportedIntervention: home-based pulmonary rehabilitation programme (including: education, exercise training, nutritional support, psychosocial support\
Methods: six weeks follow-upSpirometry; perceived dyspnoea assessment; 6MWD; MIP; CRQIntervention produced significant improvements in 6MWD, dyspnoea score, and all four domains of CRQ (dyspnoea, emotional, fatigue and mastery scores) cf. baseline, and no significant changes in MIP or spirometry\
Results of control study not clearly reportedG: 1, 2, 3, 5, 7\
P: 6, 10\
N: 4, 8, 9, 11*312004--2005; RCT; Aligarhn* = *100 (50 experimental; 50 control); moderate--severe COPD*\
*Experimental group: 76% men, mean age 62.6 (SD 6.2) years; control group: 80% men, mean age 60.1 (SD 7.3) yearsIntervention: 600 mg oral N-acetylcysteine daily for four months*\
*Methods: randomized, single-blind, placebo-controlled; one year follow-upSpirometry, exacerbation frequencyFewer exacerbations in intervention group*\
*Spirometry values increased more in intervention cf control group (although no clear increase within either group)G: 1, 2, 4*\
*P: 10*\
*N: 3, 5, 6, 7, 8, 9, 11*\
*Main concerns: recruitment, data collection and analysis not well-described*322002 -- 2004; RCT; Delhi*n* = 24 (10 experimental; 14 control); 100% men\
Experimental group: mean age 54.86 (SD 7.13) years; control group: mean age: 60.10 (SD 1.16) yearsIntervention: vitamin E supplementation\
Methods: randomized, single-blind, placebo-controlled; eight-week follow-upSpirometry; 'clinical assessment'; 'several biochemical parameters of oxidant-antioxidant status'Similar degree of lung function and clinical improvement (significant) in both groups\
Experimental group: higher plasma sulphydryls and red cell catalase cf. control group\
Plasma nitrates and nitrites decreased in control, but not experimental, groupG: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11\
P:\
N:*33P2003; observational study; Delhin* = *30 (30 COPD patients (15 experimental); \> 35 years; 80% menIntervention: 400 IU vitamin E daily*\
*Methods: randomized, control and blinding unclear; 12-week follow-up'Clinical examination', spirometry, plasma malondialdehyde, alpha-tocopherol and red cell superoxide dismutaseExperimental group: MDA levels fell over study period; no other changes in any parameters over study periodG: 1, 2, 4*\
*P: 6, 7, 10*\
*N: 3, 5, 8, 9, 11*\
*Main concerns: Recruitment unclear; no control (results reported) for period of vitamin E supplementation; only half of COPD group received vitamin E*34P2003; RCT; Jaipur*n* = 40 (20 experimental, 20 control); 80% men; 48--75 years (mean age 59.37 (SD 6.4 years)); severe COPD; never involved in pulmonary rehabilitation programme and smoking cessation for \> 2 monthsIntervention: domiciliary pulmonary rehabilitation programme\
Methods: four-week follow-up6MWD; FEV1; CRQSignificant improvement in 6MWD and CRQ scores in experimental cf. control group\
No significant change in FEV1 in either groupG: 1, 2, 3, 5, 6, 7, 9\
P: 5, 10\
N: 4, 8, 11*35P2003; RCT; Delhin* = *8; 100% men; mean age 52 yearsIntervention: Salbutamol, ipratropium bromide or beclomethasone dipropionate*\
*Methods: randomized, cross-over, placebo-controlled; each drug/placebo given randomly on four separate days; 24-hour follow-upRadioaerosol inhalation lung cinescintigraphy/mucociliary clearanceNo significant clearance with any drug, and no difference cf. placeboG: 1, 2, 5, 6, 7*\
*P: 3, 10*\
*N: 4, 8, 9, 11*\
*Main concerns: very low n-number*36P2002; RCT; Delhi*n* = 33 (17 experimental, 16 control); 100% men; moderate/severe COPD (BTS criteria)\
Experimental group: mean age 59.06 (SD 10.57) years; mean smoking history: 39.96 (SD32.2) years\
Control group: mean age 56.81 (SD 12.49) years; mean smoking history: 56.56 (SD 52.3) yearsIntervention: salmeterol\
Methods: double-blind, randomized, placebo controlled; eight-week follow-upSpirometry; 6MWT; quality-of-life questionnaire; perceived dyspnoea assessment; patient\'s self-assessment of symptoms; supplemental use of salbutamolSignificant increase in FEV1 and FVC in salmeterol group, but not placebo group, and significant effect of salmeterol in both measures versus placebo\
Salmeterol also led to greater improvements quality-of-life questionnaire, dyspnoea assessment, self-assessment of symptoms and salbutamol use6MWD similar in both groupsG: 1, 2, 3, 5, 6, 7, 9\
P: 10\
N: 4, 8, 1137P2001; quasi-crossover trial; Mysore*n* = 30; 100% men; mean age 65 (SD 7.74) years; 'mild--severe'Intervention: ipratropium or theophylline for one month, the other for second month and combination for third month\
Methods: followed up every 15 daysSpirometry, quality-of-life questionnaire, functional ability/impairment; perceived dyspnoeaFEV1 and quality-of-life scores were higher than baseline following all three treatments\
FEV1 and quality-of-life scores were significantly higher following ipratropium cf theophylline treatment, and in the combination -- cf single drug -- treated groupsG: 1, 2, 6, 7\
P: 3, 10\
N: 4, 5, 8, 9, 11\
Main concern: combination treatment not part of crossover design (administered to all participants in third month)*38P1999; RCT; Aligarhn* = *97 (32 salbutamol, 29 ipratropium and 36 combined group)*;\
*'mild-moderate symptoms'; excluded if other chronic disease*\
*Salbutamol group: 59% men; mean age 57.1 (SD 11.4) years; 69% smokers*\
*Ipratropium group: 62% men; mean age 61.7 (SD 13.7) years; 66% smokersIntervention: inhalation of salbutamol, ipratropium bromide or combination*\
*Method: salbutamol, ipratropium or both administered; four-hour follow-up*\
*Combination group: 58% men; mean age 58.6 (SD 13.1) years; 67% smokersFEV1No baseline differencesIpratropium → significantly higher mean FEV1 cf. salbutamol at 180 and 240 minutes*\
*Combination treatment → significantly higher mean FEV1 cf salbutamol at 120, 180 and 240 minutesG: 1, 2 3, 5*\
*P: 6, 7, 10*\
*N: 4, 8, 9, 11*\
*Main concerns: methods including recruitment, randomization and data analysis unclear; not all outcomes reported39P1998; quasi-experimental study; Chandigarhn* = *15; 93% men; mean age 58.9 (SD 11.05) years; volunteer patientsIntervention: yoga therapy*\
*Methods: therapy delivered for four weeksFEV1, PEFR, VC, perceived dyspnoeaYoga therapy associated with improved perceived dyspnoea, FEV1, PEFR and VC measurementsG: 1, 6, 10*\
*P: 2, 4, 5, 8*\
*N: 3, 7, 9, 11*\
*Main concerns: volunteer patients → selection bias; little information regarding methods; relatively high degree of potential bias*40P1991; parallel group study; Tamil Nadu*n* = 45 (15 per group); groups 53 -- 60% men; age range: 35--75 years\
Deriphylline group: mean age 54.5 (SD 12.6) years; 53% men; salbutamol group: 51.3 (SD 9.9) years; 60% men; terbutaline group: 47.0 (SD 5.4) years; 60% menIntervention: oral deriphylline, salbutamol or terbutaline daily\
Methods: uncontrolled, parallel group design; follow-up three weeksPEFRSignificant rise in PEFR in salbutamol and terbutaline groups\
No change in deriphylline groupG: 1, 2, 4, 5, 6, 7, 9\
P:\
N: 3, 8, 10, 11*41P1989; quasi-crossover study; Tirupatin* = *10; 100% men; 35--60 years (mean age 48.5 \[SD 9.75\] years)Intervention: inhalation of salbutamol or ipratropium bromide or combination*\
*Method: salbutamol administered on day 1, ipratropium bromide on day 2, combination on day 3; six-hour follow-upFEV1, PEFRIpratropium significantly more effective than salbutamol and the combination more so with regard to FEV1 and PEFRG: 1, 7*\
*P: 2, 3, 4, 6, 9, 10*\
*N: 5, 8, 11*\
*Main concerns: low n-number; sequential study design; high risk of bias42P1982; RCT; Delhin* = *75 (25 each group); 100 % men*\
*Control group: mean age: 49.2 (SD 10.0) years; physiotherapy group: mean age 48.1 (SD 8.44) years; yogasanas group: mean age: 50.6 (SD 12.23) yearsIntervention: breathing exercises/chest physiotherapy or yogosanas*\
*Methods: 12-week follow upSpirometry; ABG analysis; respiratory rate; heart rateBest maintenance of spirometry in yogasanas group (non-significant)*\
*Lower respiratory and heart rates in yogasanas cf. control (intermediate response in physiotherapy group)*\
*No ABG change with any treatmentG: 1, 3, 5*\
*P: 2, 6, 7, 8, 10*\
*N: 4, 9, 11*\
*Main concerns: unclear if truly randomized as FEV1/FVC ratios of groups matched; statistical methods and outcomes unclear*[^5][^6] Table 5Review of chronic obstructive pulmonary disease management outcomes in IndiaRef.Study dates and locationPopulation size and characteristicsMethods and diagnostic and assessment criteriaOutcomesQuality43*2008--2009; Bhopal, Madhya Pradesh (urban)n* = 100 (6 stage I, 32 stage 2, 40 stage 3, 22 stage 4); \> 40 years (mean age 61.7 years \[SD 9.6\]); 100% men; ex-smokers or current smokers; stable patients; excluded if prior diagnosis of depression or chronic systemic diseasesSeverity of COPD classified by GOLD criteria\
Hindi translation (validated) of PHQ-9 used to assess depressionPrevalence of depression: 72%\
Severity of depression increased with that of COPDG: 1, 2, 3, 4, 5, 6, 7, 10\
P: 9\
N: 8, 11*442007--2009; Kolkata (urban)n* = *37; severity: GOLD category 3/4; mean age (* ± *SD): 65.32* ± *9.58 years; men:women ratio 35:2Diagnosis and severity assessment by GOLD criteria*\
*BMD assessed by ultrasound bone densitometer -- T-score −1 to −2.5* = *osteopaenia, \<−2.5* = *osteoporosis*\
*Uncontrolled studyPrevalence of osteopaenia: 51.35%*\
*Prevalence of osteoporosis: 21.62%G: 1, 2, 5, 10, 11*\
*P: 3, 6, 7*\
*N: 4, 8, 9*\
*Main concerns: limited information regarding methodology, recruitment unclear; no description of analysis methods, but various comparisons performed451994--2004; Delhi (urban)n* = *515; 66% menAll deaths between 1994--2004 analysed using verbal autopsy questionnaire; causes of death recorded using International Classification of Diseases-10 codeCOPD second commonest cause of death (11.6% \[10.5% men, 13.7% women\])*\
*COPD* = *commonest cause of death in group ≥65 yearsG: 1, 5, 9*\
*P: 2, 3, 6, 7, 10*\
*N: 4, 8, 11*\
*Main concerns: limited information regarding objectives and methodology and no description of analysis methods; scope for bias relatively high*461999--2000; Chandigarh City and Panchkula district (urban and rural)*n* = 84; \> 60 yearsMean number of morbidities among the entire sample of elderly people (*n* = 200; NB. not COPD group alone) was 6.1 (SD 2.9)'Clinical diagnosis' of COPD (reported illness, clinical examination, cross-checking of medical records and medications); questionnaires for distress (physical and mental) and disabilityCOPD significantly associated with higher disability and distress scoresG: 1, 2, 3, 4, 5, 6, 7, 8, 10, 11\
P:\
N: 9*47P1992; Chandigarh (urban)n* = *150; 92.7% men; 28--78 years; smokersQuestionnaire66.7% knew disease related to smoking; 88.7% advised by doctor to stop*\
*Of patients who had given up smoking:, 52.8% due to insistence of doctor, 44% because of their own persistence, and four due to advice by friends; six suggested would resume once symptom-free, 12 undecidedG: 1*\
*P: 2, 3, 6, 7, 10*\
*N: 4, 5, 8, 9, 11*\
*Main concerns: unclear objectives, methodology and analysis; relatively high potential for bias481981--1986; Tamil Nadu (rural)n* = *9946; \> 30 yearsQuestionnaire and PEFR for COPD diagnosis; chest X-rays examined for evidence of cor pulmonale (diagnostic criteria not supplied)Of 99 patients given chest X-ray, 1 patient had cardiomegaly with clinical evidence or cor pulmonaleG: 1, 2, 11*\
*P: 3, 6, 7, 9, 10*\
*N: 4, 5, 8*\
*Main concerns: some elements of methodology and analysis unclear, information gained from family members where participants unavailable49P1982; Jhansi, Uttar Pradesh (rural)n* = *1424; \>20 years; 54.4% men*\
*14.8% men never smokers, 73.3% current smokers; 86.0% women never smokers, 12.0% women current smokersQuestionnaire for CB diagnosis; no definition for right ventricular hypertrophy/failure givenRight ventricular hypertrophy/failure in 5.4%G: 1, 2, 4, 5, 8, 9*\
*P: 3, 6, 7, 10*\
*N: 4, 8, 11*\
*Main concerns: methodology relating to determination of RVH/failure unclear; reported as an additional outcome; analysis not described*[^7][^8]

Management I -- interventions {#s3a}
-----------------------------

Twenty-nine studies of interventions were identified -- two relating to primary prevention and 27 to secondary prevention. Other than two studies published in the 1980s, and three in the 1990s, all had been published within the last decade. Generally, more recent studies had higher-quality scores.

Regarding the two primary prevention studies -- neither was a clear, trialled and audited study, and neither was conceived to address COPD alone. Although one^[@SHORTS-12-029C14]^ scored well on quality assessment, it was a theoretical study, with the associated uncertainties. The second^[@SHORTS-12-029C15]^ was a conference abstract, with poor-quality scores, and difficulty in interpretation limited its use.

The 27 studies investigating secondary prevention interventions showed much variety in intervention type, study setting and outcome measures. There were 17 pharmacological interventions, three pulmonary rehabilitation interventions, five others involving exercise training, one trial of influenza vaccination and one study of the World Health Organisation-Government of India guidelines. All were assessed using intermediate clinical outcome measures. The guidelines and vaccination interventions were assessed using a quality-of-life questionnaire and exacerbation frequency, respectively. The other categories of intervention were each assessed by a combination of spirometry, exercise capacity and other physical measures, as well as quality-of-life scores.

Of the trialled interventions, only six had negative outcomes,^[@SHORTS-12-029C21],[@SHORTS-12-029C25],[@SHORTS-12-029C27],[@SHORTS-12-029C32],[@SHORTS-12-029C35]^ and of those with positive outcomes, only the implementation of the WHO-Government of India guidelines was potentially still ongoing. Indeed, in several cases the follow-up was so limited that the relevance of the intervention was unclear.^[@SHORTS-12-029C21],[@SHORTS-12-029C23],[@SHORTS-12-029C32],[@SHORTS-12-029C38],[@SHORTS-12-029C41]^ The clinical relevance of the changes rendered by some studies^[@SHORTS-12-029C20],[@SHORTS-12-029C23],[@SHORTS-12-029C32],[@SHORTS-12-029C33],[@SHORTS-12-029C42]^ was also unclear.

Discounting these studies of questionable relevance, and those with quality concerns, only 10 studies of relatively high usability were left.^[@SHORTS-12-029C16],[@SHORTS-12-029C18],[@SHORTS-12-029C19],[@SHORTS-12-029C24],[@SHORTS-12-029C26],[@SHORTS-12-029C29],[@SHORTS-12-029C30],[@SHORTS-12-029C34],[@SHORTS-12-029C37],[@SHORTS-12-029C40]^ Notably, all of these studies had positive outcomes, but they were of varied intervention type (5 pharmacological, 2 pulmonary rehabilitation, 2 other exercise interventions and 1 regarding vaccines), and each was confined to a particular geographical area. Their generalizability was therefore limited. Four of the studies (of bronchodilator use and pulmonary rehabilitation) were of interventions already recommended in Indian guidelines. Although subgroup outcomes are of interest with regard to disease patterns and targeting interventions, the low number and heterogeneity of studies did not permit such investigation.

Management II -- outcomes {#s3b}
-------------------------

Seven studies relating to outcomes were identified -- two from the 1980s, one from the 1990s and four more recent. Again fewer quality concerns were associated with more recent studies. Many outcomes were considered: prevalence of depression, cor pulmonale, osteopaenia and osteoporosis, disability and distress scores, mortality data and management of smoking. The only process measures investigated were some relating to management of smoking.

COPD was associated with relatively high levels of depression, disability and distress.^[@SHORTS-12-029C43],[@SHORTS-12-029C46]^ It was the second commonest cause of death generally, and the highest in older age groups.^[@SHORTS-12-029C45]^ The observed extent of right ventricular failure/cor pulmonale was low -- but both of the investigating studies were relatively dated.^[@SHORTS-12-029C48],[@SHORTS-12-029C49]^ The prevalences of osteoporosis and osteopaenia were insufficiently different from estimates of general populations of the same age to be able to convincingly suggest a difference in the absence of a control group.^[@SHORTS-12-029C44]^ The study relating to education and treatment of smoking had some quality concerns, but suggested that only 88.7% of patients received cessation advice, and one-third of patients were unaware of the association between COPD and smoking.^[@SHORTS-12-029C47]^ Excluding studies with quality concerns, only those investigating depression, disability and distress remained.

Discussion {#s4}
==========

Principal findings {#s4a}
------------------

We planned an investigation to determine the extent and efficacy of the management of COPD in India. An important observation was the paucity of data and inconsistency in study setting and population characteristics. This is in contrast to some other states, such as in England, where national studies have demonstrated the availability/efficacy of current management across the region.^[@SHORTS-12-029C50]^ Study quality was also variable and of concern in 19/36 cases, but improved in recent years. These issues so impacted on analysis that we were unable to draw conclusions regarding efficacy of management under current strategies, and the extent of applicability of trialled interventions.

Data regarding management outcomes were particularly lacking. Of the few available studies, many were not conceived with this in mind, the studies were few and disparate and only two were deemed of reliable quality. They were certainly suggestive that outcomes are suboptimal, but being carried out on various ill-defined management backgrounds and varied populations, over an extended time-period, their degree of general applicability is relatively unknown.

Uncertainty is again an issue in interpretation of the review of management interventions -- almost all of which showed success in at least some outcome measures. This is especially so when, for example, pulmonary rehabilitation (a component of current guidelines) remains a subject of investigation and generates a positive response. Such data -- and the one study of process measures suggestive that smoking cessation advice (another component of the guidelines) is not consistently delivered^[@SHORTS-12-029C44]^ -- emphasize the need for the extent of current guideline implementation to be understood, before studies such as those reviewed can be most usefully applied.

The issue of the optimal extent of generalization of trialled interventions is in many respects premature. However, subgroup differences in disease prevalence, nature and course will exist, differential management strategies may be useful, and this can be usefully borne in mind as investigations continue.

Strengths and weaknesses of this study {#s4b}
--------------------------------------

Although the low number and heterogeneity of the reviewed studies were a notable outcome in themselves, they did have a considerable effect on the extent to which this review could be undertaken as planned. Further limitations on our results were imposed by (1) aspects of the review methodology and (2) our decision not to include unpublished data from trial databases.

The methodology was constrained in particular by the subjective nature of the quality assessment, and the lack of appropriateness of data for meta-analysis. The data were insufficient even for narrative synthesis in some areas of investigation. Regarding our decision not to include data from trial databases, we accept that our thus relatively constrained inclusion criteria may have increased the possibility of reporting bias. Indeed the observed outcomes regarding management interventions would allow that these data may have been at risk of publication bias.

We hope, though, that our thorough, systematic approach has identified most of the available data, and helped to provide a useful, clear summary, demonstrative of where the gaps in knowledge lie.

Interpretation of findings in relation to previously published work {#s4c}
-------------------------------------------------------------------

Comparing outcomes of COPD management in India with those elsewhere is hindered mainly by the paucity of data. The management guidelines utilized in India are based on those recommended by international bodies and utilized elsewhere. They reflect disease pattern and context in India to an extent,^[@SHORTS-12-029C51]^ but do not really reflect that the included strategies tend to have been developed from study of populations resident in more developed states, and that the extent to which they can be similarly applied to other populations -- including Indian populations -- is unclear. The reviewed intervention and outcome studies are indicative that aspects of the current programme should be beneficial, but further study is required to determine that the guidelines are sufficiently effective in this population, and to investigate any subpopulation subtleties with regard to treatment outcomes. For example, the nature of the disease associated with domestic, and other environmental, pollution (relatively prevalent in this population) -- rather than that associated with smoking -- is less well characterized. Similarly, the nature of the disease when associated with HIV/tuberculosis is unclear,^[@SHORTS-12-029C3]^ and issues such as poor nutrition may well be of relevance to management.^[@SHORTS-12-029C6]^

Study of primary prevention was conspicuously lacking. The existing management guidelines do include reduction of risk factors, but these need to be implemented as more general societal measures (i.e. as primary rather than secondary prevention), and it is not clear that this is being achieved. Although a smoking ban was introduced in India in 2008, media reports of successful implementation of the ban are mixed. Ensuring achievement of the ban is a priority, and additional programmes such as those modelled by Wilkinson *et al.*^[@SHORTS-12-029C14]^ and further demotion of smoking activities, would be of use. The reviewed study of a smoking cessation programme^[@SHORTS-12-029C15]^ was difficult to interpret, but it is likely cessation programmes would be usefully applied -- particularly when associated with an education component -- for which there is an evident need.^[@SHORTS-12-029C47],[@SHORTS-12-029C52]^ A review of smoking cessation programmes in India, their outcomes and associated research, would probably be useful.

Implications for future research, policy and practice {#s4d}
-----------------------------------------------------

Although many of the studies reviewed here do contain potentially useful management strategies, these options, and others, could be better assessed and implemented if the distribution and success of current management was better understood. It might be useful to initially: Achieve a better understanding of disease prevalence and likely trends in prevalence, as we have recently suggested;^[@SHORTS-12-029C9]^Audit the use of guidelines -- in terms of both process and clinical outcomes -- across the country;Estimate the proportion of the population accessing health-care services, and the proportion to which optimal/guideline care is available and taken-up.This information would provide a useful background on which study of more subtle themes -- such as those relating to the nature of disease among subgroups, and how best to target resources -- could be based.

In the interim, the lack of data should not preclude the implementation of potentially useful interventions. Our review has shown that many secondary prevention methods would be beneficial, and that primary prevention methods are especially needed, and could be usefully implemented with ongoing review. In addition to consideration of change in domestic fuel use and tackling the extent of smoking, occupational health is another important primary prevention issue. In our review, we excluded studies investigating occupational groups alone, but several occupational groups are understood to be at relatively great risk,^[@SHORTS-12-029C53]^ and need particular attention, especially in terms of preventive interventions.

Conclusions {#s5}
===========

Investigation of the current extent of management of COPD in India is hindered by the number and nature of studies available. High-quality current data from a cross-section of the population is required if the current quality of management is to be determined at a level useful for policy considerations. An understanding of the extent of implementation of national guidelines would be particularly useful, and it would also be helpful to understand the current use of important preventive measures, particularly those targeting smoking, domestic fuel use and occupational risk. This would provide a useful background on which the efficacy of further management strategies -- including some of those successfully trialled to date -- could be usefully examined. The specific needs of subgroups could also then be further investigated and addressed.

In addition, optimal long-term solutions will require provision of more comprehensive prevalence estimates than are currently available, review of the changing context of service delivery and implementation of a more general approach to chronic disease management.
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